VICARIOUS SURGICAL INC-A (RBOT) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:RBOT - US92561V2088 - Common Stock
2.3 USD
-0.21 (-8.37%)
2.35 USD
+0.05 (+2.17%)
Overall RBOT gets a fundamental rating of 2 out of 10. We evaluated RBOT against 184 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for RBOT as it has an excellent financial health rating, but there are worries on the profitability. RBOT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- RBOT had negative earnings in the past year.
- RBOT had a negative operating cash flow in the past year.
- In the past 5 years RBOT reported 4 times negative net income.
- RBOT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -182.62%, RBOT is doing worse than 88.59% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -380.42%, RBOT is doing worse than 78.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -182.62% | ||
| ROE | -380.42% | ||
| ROIC | N/A |
ROA(3y)-49.66%
ROA(5y)-48.14%
ROE(3y)-67.76%
ROE(5y)-64.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of RBOT (5.76%) is worse than 81.52% of its industry peers.
- The Profit Margin and Operating Margin are not available for RBOT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 5.76% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RBOT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for RBOT has been increased compared to 1 year ago.
- RBOT has less shares outstanding than it did 5 years ago.
- RBOT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -15.69, we must say that RBOT is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of RBOT (-15.69) is worse than 83.70% of its industry peers.
- RBOT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.69 |
ROIC/WACCN/A
WACC10.02%
2.3 Liquidity
- A Current Ratio of 4.75 indicates that RBOT has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 4.75, RBOT is in the better half of the industry, outperforming 76.63% of the companies in the same industry.
- A Quick Ratio of 4.75 indicates that RBOT has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 4.75, RBOT belongs to the top of the industry, outperforming 82.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.75 | ||
| Quick Ratio | 4.75 |
3. Growth
3.1 Past
- RBOT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.05%, which is quite good.
- Looking at the last year, RBOT shows a very strong growth in Revenue. The Revenue has grown by 160.31%.
EPS 1Y (TTM)12.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.86%
Revenue 1Y (TTM)160.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 19.05% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.95%
EPS Next 2Y27.18%
EPS Next 3Y19.05%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- RBOT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year RBOT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RBOT's earnings are expected to grow with 19.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.18%
EPS Next 3Y19.05%
5. Dividend
5.1 Amount
- RBOT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
VICARIOUS SURGICAL INC-A / RBOT FAQ
What is the ChartMill fundamental rating of VICARIOUS SURGICAL INC-A (RBOT) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RBOT.
What is the valuation status of VICARIOUS SURGICAL INC-A (RBOT) stock?
ChartMill assigns a valuation rating of 0 / 10 to VICARIOUS SURGICAL INC-A (RBOT). This can be considered as Overvalued.
What is the profitability of RBOT stock?
VICARIOUS SURGICAL INC-A (RBOT) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for RBOT stock?
The Earnings per Share (EPS) of VICARIOUS SURGICAL INC-A (RBOT) is expected to grow by 23.95% in the next year.